Device can pinpoint neurological biomarkers; Heart disease biomarker points to new asthma strategy;

> A German Parkinson's patient was the first to be treated with Medtronic's ($MDT) Activa PC+S device, an implant that administers standard DBS therapy all while sensing and recording electrical activity in key areas of the brain, something impossible before now, the company said. "The eventual goal of the PC+S is to define and clarify the biomarkers of neurological disorders," Medtronic engineer Tim Denison said in an interview with FierceMedicalDevices. "The next step will be to use that information to define what the optimal policies are for closing the loop." Story

> Targeting a key enzyme associated with heart disease could offer a new way to treat asthma, which affects billions of people worldwide, including 8.5% of the U.S. population. Report

> A consensus statement notes that "CK-MB should be preferred over cardiac troponin (cTn) to identify coronary angioplasty-related myocardial injury that predicts later events." Report

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.